Morgan Stanley: Gives Moderna (NASDAQ:MRNA) a “hold” rating with a $209 price target

By / / Moderna, Morgan Stanley

According to Morgan Stanley, vaccine data will drive shares higher, giving Moderna (NASDAQ:MRNA) a “hold” rating with a $209 price target.

Scroll to Top